Verona Pharma Plc (LON:VRP) insider Piers Morgan bought 20,132 shares of Verona Pharma stock in a transaction dated Friday, March 22nd. The stock was acquired at an average price of GBX 64 ($0.84) per share, with a total value of £12,884.48 ($16,835.86).

LON VRP opened at GBX 60.50 ($0.79) on Wednesday. Verona Pharma Plc has a 1-year low of GBX 48 ($0.63) and a 1-year high of GBX 200 ($2.61). The firm has a market capitalization of $63.72 million and a PE ratio of -3.20.

VRP has been the topic of a number of research reports. Shore Capital reaffirmed a “buy” rating on shares of Verona Pharma in a research note on Monday, March 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Verona Pharma in a research note on Friday, January 4th.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Featured Story: Why Invest in Dividend Achievers?

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with's FREE daily email newsletter.